ArticleACS medicinal chemistry letters2017
Discovery of VU6005649, a CNS Penetrant mGlu
Abstract read
In one paragraph
Article in ACS medicinal chemistry letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Molecular pharmacology of mGluMolecular pharmacology · 2026Article
- Suppression of neuropathic pain hypersensitivity by TRPM8 is mediated by mGluR group II and III receptors acting differentially on distinct nociceptor inputs to spinal cord.Frontiers in pharmacology · 2026Article
- Profiling the Impact of mGluACS chemical neuroscience · 2025Article
- Role of mGluR7 in Alzheimer's disease: pathophysiological insights and therapeutic approaches.Inflammopharmacology · 2025Review
- mGlu4R, mGlu7R, and mGlu8R allosteric modulation for treating acute and chronic neurodegenerative disorders.Pharmacological reports : PR · 2024Review
- KACS omega · 2023Article
- Differential Activity of Orthosteric Agonists and Allosteric Modulators at Metabotropic Glutamate Receptor 7.Molecular pharmacology · 2023Article
- GRM7 gene mutations and consequences for neurodevelopment.Pharmacology, biochemistry, and behavior · 2023Review
- Design and Synthesis of New Quinazolin-4-one Derivatives with Negative mGluInternational journal of molecular sciences · 2023Article
- Insights into the medicinal chemistry of heterocycles integrated with a pyrazolo[1,5-RSC medicinal chemistry · 2022Review
- Classification models and SAR analysis on CysLT1 receptor antagonists using machine learning algorithms.Molecular diversity · 2021Article
- Functional Pyrazolo[1,5-Molecules (Basel, Switzerland) · 2021Review
- Synthesis and SAR of a series of mGluBioorganic & medicinal chemistry letters · 2020Article
- Discovery of VU6027459: A First-in-Class Selective and CNS Penetrant mGluACS medicinal chemistry letters · 2020Article
- Discovery of an Orally Bioavailable and Central Nervous System (CNS) Penetrant mGluJournal of medicinal chemistry · 2019Article
- Progress toward allosteric ligands of metabotropic glutamate 7 (mGlu7) receptor: 2008-present.MedChemComm · 2019Review
- Metabotropic Glutamate Receptor 7: A New Therapeutic Target in Neurodevelopmental Disorders.Frontiers in molecular neuroscience · 2018Review
- Corrigendum: Metabotropic Glutamate Receptor 7: A New Therapeutic Target in Neurodevelopmental Disorders.Frontiers in molecular neuroscience · 2018Article
- VU6010608, a Novel mGluACS medicinal chemistry letters · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Masahito AbeDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Mabel SetoDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Rocco G GogliottiDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Matthew T LochDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Katrina A BollingerVanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Sichen ChangVanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Eileen M EngelbergDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Vincent B LuscombeDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Joel M HarpDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Michael BubserDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Darren W EngersDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Carrie K JonesDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Alice L RodriguezDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Anna L BlobaumDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
P Jeffrey ConnDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Colleen M NiswenderDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Craig W LindsleyDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Funding
TRAINING IN PHARMACOLOGICAL SCIENCEST32GM007628 · NIGMS · VANDERBILT UNIVERSITY · PI BARNETT, JOEY VICTOR, KAVALALI, EGE T · 1985 to 2022
$11.2MResearch Project: Sensory and Multisensory Contributions to AutismU54HD083211 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DYKENS, ELISABETH MAY · 2015 to 2019
$7.1MProgram in NeurogenomicsT32MH065215 · NIMH · VANDERBILT UNIVERSITY · PI ROGER J COLBRAN · 2002 to 2026
$6.4MDevelopment of a Selective Metabotropic Glutamate Receptor 7 Allosteric Modulator ProbeR01MH113543 · NIMH · VANDERBILT UNIVERSITY · PI LINDSLEY, CRAIG, NISWENDER, COLLEEN M · 2017 to 2019
$1.2MMetabotropic Glutamate Receptor Regulation in MeCP2-Related DisordersR21MH102548 · NIMH · VANDERBILT UNIVERSITY · PI NISWENDER, COLLEEN M · 2014 to 2015
$431kNICHD NIH HHS U54 HD083211NIGMS NIH HHS T32 GM007628NIMH NIH HHS R01 MH113543NIMH NIH HHS R21 MH102548NIMH NIH HHS T32 MH065215
Abstract
Herein, we report the structure-activity relationships within a series of mGlu
Indexed as
cognitionmetabotropic glutamate receptor 7 (mGlu7)Positive allosteric modulator (PAM)Rett syndromeVU6005649
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.